Neurocrine Biosciences Given New $23.00 Price Target at Jefferies Group (NBIX)
Investment analysts at Jefferies Group hoisted their target price on shares of Neurocrine Biosciences (NASDAQ:NBIX) from $16.00 to $23.00 in a note issued to investors on Wednesday, AnalystRatingsNetwork.com reports. Jefferies Group’s price target points to a potential upside of 27.21% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank raised their price target on shares of Neurocrine Biosciences from $18.00 to $25.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at MKM Partners raised their price target on shares of Neurocrine Biosciences from $13.00 to $17.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of Neurocrine Biosciences from $16.00 to $22.00 in a research note to investors on Tuesday. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $18.73.
In other Neurocrine Biosciences news, Insider Dimitri E. Grigoriadis sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $17.50, for a total value of $437,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down 2.34% on Wednesday, hitting $18.08. The stock had a trading volume of 4,215,930 shares. Neurocrine Biosciences has a 52 week low of $8.30 and a 52 week high of $18.62. The stock’s 50-day moving average is $9.70 and its 200-day moving average is $11.79. The company’s market cap is $1.218 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Tuesday, October 29th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.20) by $0.03. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter last year, the company posted ($0.05) earnings per share. Neurocrine Biosciences’s revenue was down 92.2% compared to the same quarter last year. On average, analysts predict that Neurocrine Biosciences will post $-0.70 earnings per share for the current fiscal year.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.